Varian Medical Systems Inc. (NYSE:VAR) changed by 0.00% from its latest closing price compared to the recent 1-year high of $176.19. The company’s stock price has collected 0.11% of gains in the last five trading sessions. Press Release reported on 09/25/20 that Lifshitz Law Firm, P.C. Announces Investigation of Akcea Therapeutics, Inc. (NASDAQ: AKCA), BMC Stock Holdings, Inc. (NASDAQ: BMCH), Builders FirstSource, Inc. (NASDAQ: BLDR), Cancer Genetics, Inc. (NASDAQ: CGIX), Cellular Biomedicine Group, Inc. (NASDAQ: CBMG), Otelco Inc. (NASDAQ: OTEL), Rosetta
Is It Worth Investing in Varian Medical Systems Inc. (NYSE :VAR) Right Now?
Varian Medical Systems Inc. (NYSE:VAR) scored a price-to-earnings ratio above its average ratio, recording 60.39 x from its present earnings ratio. Plus, the 36-month beta value for VAR is at 1.12. Opinions of the stock are interesting as 2 analysts out of 8 who provided ratings for Varian Medical Systems Inc. declared the stock was a “buy,” while 1 rated the stock as “overweight,” 5 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $177.67, which is $5.64 above the current price. VAR currently public float of 90.65M and currently shorts hold a 4.87% ratio of that float. Today, the average trading volume of VAR was 1.46M shares.
VAR’s Market Performance
VAR stocks went up by 0.11% for the week, with a monthly drop of -0.96% and a quarterly performance of 41.54%, while its annual performance rate touched 48.79%. The volatility ratio for the week stands at 0.27% while the volatility levels for the past 30 days are set at 0.40% for Varian Medical Systems Inc.. The simple moving average for the period of the last 20 days is -0.59% for VAR stocks with a simple moving average of 27.03% for the last 200 days.
Analysts’ Opinion of VAR
UBS, on the other hand, stated in their research note that they expect to see VAR reach a price target of $177.50, previously predicting the price at $150. The rating they have provided for VAR stocks is “Neutral” according to the report published on August 06th, 2020.
Evercore ISI gave a rating of “In-line” to VAR, setting the target price at $177.50 in the report published on August 03rd of the current year.
VAR Trading at 3.70% from the 50-Day Moving Average
After a stumble in the market that brought VAR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -2.38% of loss for the given period.
Volatility was left at 0.40%, however, over the last 30 days, the volatility rate increased by 0.27%, as shares sank -1.04% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +33.76% upper at present.
During the last 5 trading sessions, VAR rose by +0.11%, which changed the moving average for the period of 200-days by +21.53% in comparison to the 20-day moving average, which settled at $172.93. In addition, Varian Medical Systems Inc. saw 21.12% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at VAR starting from WILSON DOW R, who sale 38,907 shares at the price of $172.43 back on Sep 21. After this action, WILSON DOW R now owns 82,564 shares of Varian Medical Systems Inc., valued at $6,708,730 using the latest closing price.
KENNEDY KOLLEEN T, the Pres. Proton Solutions, CGO of Varian Medical Systems Inc., sale 400 shares at $173.48 during a trade that took place back on Sep 14, which means that KENNEDY KOLLEEN T is holding 27,118 shares at $69,392 based on the most recent closing price.
Stock Fundamentals for VAR
Current profitability levels for the company are sitting at:
- +15.49 for the present operating margin
- +43.32 for the gross margin
The net margin for Varian Medical Systems Inc. stands at +9.05. The total capital return value is set at 26.45, while invested capital returns managed to touch 17.41. Equity return is now at value 14.20, with 6.10 for asset returns.
Based on Varian Medical Systems Inc. (VAR), the company’s capital structure generated 23.19 points at debt to equity in total, while total debt to capital is 18.82.
Currently, EBITDA for the company is 111.10M with total debt to EBITDA at 0.71. When we switch over and look at the enterprise to sales, we see a ratio of 3.33, with the company’s debt to enterprise value settled at 0.04. The receivables turnover for the company is 2.92 and the total asset turnover is 0.88. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.27.